Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

L.A. McKeown

September 27, 2018

Presentation TCT 2018

SAPIEN M3 Transcatheter Mitral Valve Replacement System: 30-Day Outcomes From the US Early Feasibility Study

Presenter: Charles J. Davidson, Francesco Maisano, Raj Makkar

September 24, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

Shelley Wood

September 23, 2018

News Conference News TCT 2018

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

Yael L. Maxwell

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

TCT-73: Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a controlled prospective randomized trial

Presenter: Rebecca T. Hahn, Jose Luis Navia, Maurizio Taramasso, Henryk Dreger

September 21, 2018

Video

» Interview

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

May 11, 2018

Advertisement

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

SAPIEN M3 Transcatheter Mitral Valve Replacement System: 30-Day Outcomes From the US Early Feasibility Study

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

High Mortality but Durable Results With Valve-in-Valve TAVR

TCT-73: Treatment of Severe TRIcuspid Regurgitation in Patients with Advanced Heart Failure with CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL): a controlled prospective randomized trial

TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content